Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ArmA:GFH375 · 1 trial · 1 indication
Objective response rate (ORR) assessed by RECIST 1.1 according to researchers
| Arm | Type | Description |
|---|---|---|
| Arm A:GFH375 | EXPERIMENTAL | Arm A :will enroll participants with previously untreated advanced NSCLC harboring KRAS G12D mutations. |
| Arm B:GFH375 in combination with Cetuximab | EXPERIMENTAL | Arm B will enroll participants with previously untreated advanced NSCLC harboring KRAS G12D mutations. |
| Arm C:GFH375 in combination with Pemetrexed | EXPERIMENTAL | Arm C will enroll participants with previously untreated advanced NSCLC harboring KRAS G12D mutations. |
| Name | Type | Description |
|---|---|---|
| ArmA:GFH375 | DRUG | GFH375 once daily (QD) 28 days as a cycle. |
| Arm B:GFH375 | DRUG | GFH375 once daily (QD) .Cetuximab will be administered via intravenous infusion at a dose of 500 mg/m² every 2 weeks. |
| Arm C:GFH375 | DRUG | GFH375 once daily (QD) .Pemetrexed disodium will be administered via intravenous infusion at a dose of 500 mg/m² every 3 weeks. |
Inclusion Criteria: 1. Voluntarily agree to participate in this study and sign the written informed consent form. 2. Male or female, aged 18 to 75 years at the time of signing the informed consent form. 3. Pathologically (histologically or cytologically) confirmed advanced (Stage IV) or locally adv...
ArmA:GFH375 is an investigational small molecule being developed for the treatment of advanced non-small cell lung cancer (NSCLC). It is being studied in patients with KRAS G12D-mutant NSCLC as a first-line treatment, both as a monotherapy and in combination therapy.
ArmA:GFH375 is being developed by cbdMD, Inc., a company traded on the NYSE American under the ticker symbol YCBD. The company is conducting clinical trials for this investigational drug in advanced non-small cell lung cancer.
ArmA:GFH375 is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 2 trial is designed to evaluate its safety and efficacy in patients with advanced KRAS G12D-mutant non-small cell lung cancer.
ArmA:GFH375 is being evaluated in a Phase 2 clinical trial with the identifier NCT07554859. This trial is studying the drug as a first-line treatment for advanced KRAS G12D-mutant non-small cell lung cancer, both as a monotherapy and in combination therapy. The trial is planned to enroll 90 participants in China.
Yes, ArmA:GFH375 is also known as GFH375. The drug is being studied under the name GFH375 in clinical trials, and ArmA:GFH375 is an alternative designation for the same investigational small molecule.
ArmA:GFH375 is being studied in patients with KRAS G12D-mutant non-small cell lung cancer, indicating that the drug is designed to target tumors with this specific genetic mutation. The clinical trial specifically enrolls patients with KRAS G12D mutations, suggesting the drug's mechanism is related to this molecular target.